Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib vs Carboplatin-Paclitaxel in HRd Stage III/IV Ovarian Cancer
NCT06964165Phase 2Terminated
- Start
- Apr 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of niraparib in ovarian cancer (2 cohorts). Primary endpoint: Pre-Interval Debulking Surgery Unconfirmed Overall Response Rate at 102 weeks. Started Apr 2022; status: terminated.
02
Drugs
niraparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06964165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06964165.